TUEBINGEN, Germany, October 15, 2013 /PRNewswire/ --
immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015
Funding secured within existing investor group
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing......
More...
